Evidence map›Paper›PMID 37515456›Full record

ArticleAllergy2024

Patients with naproxen-induced liver injury display T-cell memory responses toward an oxidative (S)-O-desmethyl naproxen metabolite but not the acyl glucuronide.

Paul Thomson, Nik Fragkas, Laila M Kafu, Guruprasad P Aithal, M Isabel Lucena, Luigi Terracciano, Xiaoli Meng, Munir Pirmohamed, Dominique Brees, Gerd A Kullak-Ublick and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Protein Haptenation and Its Role in Allergy.Chemical research in toxicology · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Paul ThomsonMolecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.ORCID 0000-0001-5431-0459
Nik FragkasNovartis Institutes for BioMedical Research, Basel, Switzerland.
Laila M KafuMolecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Guruprasad P AithalNIHR Nottingham Biomedical Research Centre and Nottingham Digestive Diseases Centre, Translational Medical Sciences, West Block, Queen's Medical Centre, University of Nottingham, Nottingham, UK.
M Isabel LucenaUnidad de Gestión Clínica de Aparato Digestivo y Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, CIBERehd, Malaga, Spain.
Luigi TerraccianoInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Xiaoli MengMolecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Munir PirmohamedMolecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Dominique BreesNovartis Institutes for BioMedical Research, Basel, Switzerland.
Gerd A Kullak-UblickUniversity Hospital Zurich, University of Zurich, Zurich, Switzerland.
Alex OdermattDivision of Molecular & Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Thomas HammondDivision of Molecular & Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Michael KammüllerNovartis Institutes for BioMedical Research, Basel, Switzerland.
Dean J NaisbittMolecular& Clinical Pharmacology, University of Liverpool, Liverpool, UK.ORCID 0000-0003-4107-7832
University of Liverpool · GBNovartis (Switzerland) · CHUniversity of Basel · CHCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESUniversity Hospital of Basel · CHUniversity of Nottingham · GB

Funding

Medical Research Council G0700654Medical Research Council MR/R009635/1
6 · The paper itself

Abstract

backgroundExposure to nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI). Carboxylate bioactivation into reactive metabolites (e.g., acyl glucuronides, AG) and resulting T-cell activation is hypothesized as causal for this adverse event. However, conclusive evidence supporting this is lacking.

methodsIn this work, we identify CD4

resultsCD4

conclusionOur results confirm hepatic T-cell infiltrations in NSAID-induced DILI, and show a T-cell memory response toward DM-NAP indicating an immune-mediated basis for the adverse event. Whilst bioactivation at the carboxylate group is widely hypothesized to be pathogenic for NSAID associated DILI, we found no evidence of this with NAP.

Indexed as

Chemical and Drug Induced Liver Injury, ChronicNaproxenAnti-Inflammatory Agents, Non-SteroidalCD8-Positive T-LymphocytesGlucuronidesHumansIbuprofenLeukocytes, MononuclearLymphocyte ActivationOxidative StressAnti-Inflammatory Agents, Non-SteroidalGlucuronidesIbuprofenNaproxendrug-induced liver injuryhumanimmune systemT lymphocytes

Identifiers

PMID37515456
PMCPMC10952231
OpenAlexW4385377544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.